Newcastle Disease Virus Enhances the Growth-inhibiting and Proapoptotic Effects of Temozolomide on Glioblastoma Cells in Vitro and in Vivo

Overview

Journal Sci Rep

Specialty Science

Date 2018 Aug 2

PMID 30065314

Citations 33

Authors

Yang Bai

Yong Chen

Xinyu Hong

Xinrui Liu

Xing Su

Shanji Li

Xuechao Dong

Gang Zhao

Yunqian Li

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is the most serious and most common brain tumor in humans. Despite recent advances in the diagnosis of GBM and the development of new treatments, the prognosis of patients has not improved. Multidrug resistance, particularly resistance to temozolomide (TMZ), is a challenge in combating glioma, and more effective therapies are needed. Complementary treatment with the LaSota strain of the naturally oncolytic Newcastle disease virus (NDV-LaSota) is an innovation. In our experiments, the combination therapy of NDV-LaSota and temozolomide (TMZ) was more effective than either treatment alone in inducing apoptosis in glioma cells. NDV can function as a tumor cell selective approach to inhibit AKT and activate AMPK. Consequently, mTOR, 4EBP1 and S6K were also suppressed. The combination therapy of NDV and TMZ also significantly extended survival in a rat xenograft tumor model. In conclusion, NDV suppress AKT signaling and enhances antitumor effects of TMZ. Our study provides one of the theoretical basis for the use of a combined therapy of TMZ and NDV, which could benefit GBM patients.

Citing Articles

Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas.

Melendez-Vazquez N, Gomez-Manzano C, Godoy-Vitorino F Viruses. 2024; 16(11).

PMID: 39599889 PMC: 11599061. DOI: 10.3390/v16111775.

Role of T Lymphocytes in Glioma Immune Microenvironment: Two Sides of a Coin.

Noor L, Upadhyay A, Joshi V Biology (Basel). 2024; 13(10).

PMID: 39452154 PMC: 11505600. DOI: 10.3390/biology13100846.

Cell and gene therapy in neuro-oncology.

Varela M, Comba A, Faisal S, Argento A, Pena Aguelo J, Candolfi M Handb Clin Neurol. 2024; 205:297-315.

PMID: 39341660 PMC: 11441620. DOI: 10.1016/B978-0-323-90120-8.00009-5.

Newcastle Disease Virus Virotherapy: Unveiling Oncolytic Efficacy and Immunomodulation.

Zaher K, Alrahimi J, Basingab F, Aldahlawi A Biomedicines. 2024; 12(7).

PMID: 39062070 PMC: 11274839. DOI: 10.3390/biomedicines12071497.

Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.

Salvato I, Marchini A Cancers (Basel). 2024; 16(7).

PMID: 38610954 PMC: 11010873. DOI: 10.3390/cancers16071276.

References

Reichard K, Lorence R, Cascino C, Peeples M, Walter R, Fernando M . Newcastle disease virus selectively kills human tumor cells. J Surg Res. 1992; 52(5):448-53. DOI: 10.1016/0022-4804(92)90310-v. View

Parker J, Bauer D, Cody J, Markert J . Oncolytic viral therapy of malignant glioma. Neurotherapeutics. 2009; 6(3):558-69. PMC: 3980727. DOI: 10.1016/j.nurt.2009.04.011. View

Reni M, Mazza E, Zanon S, Gatta G, Vecht C . Central nervous system gliomas. Crit Rev Oncol Hematol. 2017; 113:213-234. DOI: 10.1016/j.critrevonc.2017.03.021. View

Jin J, Hwang K, Joo J, Han J, Kim C . Combination therapy of 7-O-succinyl macrolactin A tromethamine salt and temozolomide against experimental glioblastoma. Oncotarget. 2018; 9(2):2140-2147. PMC: 5788628. DOI: 10.18632/oncotarget.23295. View

Jakubowicz-Gil J, Badziul D, Langner E, Wertel I, Zajac A, Rzeski W . Temozolomide and sorafenib as programmed cell death inducers of human glioma cells. Pharmacol Rep. 2017; 69(4):779-787. DOI: 10.1016/j.pharep.2017.03.008. View

MATUMOTO M . Enhanced replication of Newcastle disease virus in cell culture co-infected with certain other viruses. Jpn J Microbiol. 1968; 12(4):505-30. DOI: 10.1111/j.1348-0421.1968.tb00424.x. View

Hirose Y, Katayama M, Mirzoeva O, Berger M, Pieper R . Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res. 2005; 65(11):4861-9. DOI: 10.1158/0008-5472.CAN-04-2633. View

Zhang J, Stevens M, Bradshaw T . Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2011; 5(1):102-14. DOI: 10.2174/1874467211205010102. View

Hu L, Sun S, Wang T, Li Y, Jiang K, Lin G . Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy. Am J Cancer Res. 2016; 5(12):3612-23. PMC: 4731635. View

10.

Sui H, Wang K, Xie R, Li X, Li K, Bai Y . NDV-D90 suppresses growth of gastric cancer and cancer-related vascularization. Oncotarget. 2017; 8(21):34516-34524. PMC: 5470987. DOI: 10.18632/oncotarget.16563. View

11.

Caporali S, Levati L, Starace G, Ragone G, Bonmassar E, Alvino E . AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol. 2008; 74(1):173-83. DOI: 10.1124/mol.107.044743. View

12.

Oike T, Suzuki Y, Sugawara K, Shirai K, Noda S, Tamaki T . Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. PLoS One. 2013; 8(11):e78943. PMC: 3827088. DOI: 10.1371/journal.pone.0078943. View

13.

Wu Y, He J, An Y, Wang X, Liu Y, Yan S . Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy. J Pharmacol Sci. 2016; 132(1):24-30. DOI: 10.1016/j.jphs.2016.03.012. View

14.

Manning B, Toker A . AKT/PKB Signaling: Navigating the Network. Cell. 2017; 169(3):381-405. PMC: 5546324. DOI: 10.1016/j.cell.2017.04.001. View

15.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

16.

Foreman P, Friedman G, Cassady K, Markert J . Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics. 2017; 14(2):333-344. PMC: 5398989. DOI: 10.1007/s13311-017-0516-0. View

17.

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

18.

Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G . NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Cancer Lett. 2015; 367(1):58-68. DOI: 10.1016/j.canlet.2015.07.007. View

19.

Bressy C, Hastie E, Grdzelishvili V . Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy. Mol Ther Oncolytics. 2017; 5:20-40. PMC: 5415316. DOI: 10.1016/j.omto.2017.03.002. View

20.

An Y, Liu T, He J, Wu H, Chen R, Liu Y . Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model. J Biomed Sci. 2016; 23(1):55. PMC: 4964062. DOI: 10.1186/s12929-016-0273-0. View